"Serum and dietary vitamin D and cardiovascular disease risk in elderly men: A prospective cohort study," Nutrition, Metabolism and Cardiovascular Diseases (Vol: 22, Issue: 10, Page 856-863) - 2012
"Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B," Nature Medicine (Vol: 18, Issue: 9, Page 1359-1368) - 2012
"Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: A phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium," British Journal of Cancer (Vol: 107, Issue: 5, Page 808-813) - 2012
"Cell membrane water exchange effects in prostate DCE-MRI," Journal of Magnetic Resonance (Vol: 218, Issue: , Page 77-85) - 2012
"Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer," Clinical Genitourinary Cancer (Vol: 10, Issue: 1, Page 6-14) - 2012
"The Exercising Together project: Design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer," Contemporary Clinical Trials (Vol: 33, Issue: 2, Page 342-350) - 2012
"C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results," Urologic Oncology: Seminars and Original Investigations (Vol: 30, Issue: 1, Page 33-37) - 2012
"HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia," Journal of Biological Chemistry (Vol: 286, Issue: 44, Page 38095-38102) - 2011
"Toward predictors of survival in castration-resistant prostate cancer," Cancer (Vol: 117, Issue: 17, Page 3882-3884) - 2011
"Prostate cancer and vitamin D: What does the evidence really suggest?," Urologic Clinics of North America (Vol: 38, Issue: 3, Page 333-342) - 2011
"New therapies for castration-resistant prostate cancer: Efficacy and safety," European Urology (Vol: 60, Issue: 2, Page 279-290) - 2011
"Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer," Clinical Cancer Research (Vol: 17, Issue: 13, Page 4558-4567) - 2011
"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma," Science Translational Medicine (Vol: 3, Issue: 85, Page ) - 2011
"Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the department of defense prostate cancer clinical trials consortium," Cancer (Vol: 117, Issue: 11, Page 2419-2425) - 2011
"A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma," Investigational New Drugs (Vol: 29, Issue: 2, Page 374-379) - 2011
"Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy," Anticancer Research (Vol: 31, Issue: 3, Page 973-974) - 2011
"Acupuncture for hot flashes in patients with prostate cancer," Urology (Vol: 76, Issue: 5, Page 1182-1188) - 2010
"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer," Cancer Research (Vol: 70, Issue: 20, Page 7992-8002) - 2010
"Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men," Cancer Causes and Control (Vol: 21, Issue: 8, Page 1297-1303) - 2010
"ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21 (Cancer Research (2010) 70, (3239-3248) DOI:10.1158/0008-5472. CAN-09-3186)," Cancer Research (Vol: 70, Issue: 11, Page 4785-) - 2010
